Max Healthcare Institute Ltd Grants Stock Options to Employees Under ESOP 2022
Max Healthcare Institute Ltd has approved the grant of stock options to eligible employees under its Employee Stock Option Scheme 2022 (MHIL ESOP - 2022). The decision was made by the Nomination and Remuneration Committee (NRC) of the company.The NRC meeting confirmed the allocation of a total of 3,61,827 stock options to employees under the MHIL ESOP - 2022. These options are linked to the grant of equity shares with a face value of ₹10 each.
Details regarding the options granted were presented across two categories within the scheme, which involve different pricing structures and quantities:
| Detail | Category 1 (Employees) | Category 2 (Employee) |
|---|---|---|
| Number of Stock Options Granted | 1,61,827 | 2,00,000 |
| Grant Price per Option | ₹800 | ₹350 |
| Shares Covered by Options | 1,61,827 equity shares | 2,00,000 equity shares |
The MHIL ESOP - 2022 is structured to ensure that the options are administered and implemented by the Nomination and Remuneration Committee. Both sets of granted options adhere to standard terms for employee benefits under the scheme.
Key terms pertaining to the stock option grants include:
- Vesting Schedule: The options are subject to pre-vesting conditions, which must be met. Vesting will occur not earlier than one year and not later than five years from the date of grant.
- Exercise Period: Employees have three years from the respective date of vesting to exercise their stock options.
The scheme further mandates that all granted options comply with SEBI regulations regarding share-based employee benefits, in addition to being administered by the NRC.
MAXHEALTH Stock Price Movement
Shares of Max Healthcare Institute Limited shed 3.13% on Wednesday, closing at ₹1007.5 after trading ended. The stock settled during the session with a volume of 2.76 million shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.